Pre-Clinical Analysis of Changes in Intra-cellular Biochemistry of Glioblastoma Multiforme (GBM) Cells Due to c-Myc Silencing

Cellular and Molecular Neurobiology

Volumn 34, Issue 7, 2014, Pages 1059-1069

  Rajagopalan, Vishal ^a   Vaidyanathan, Muthukumar ^a   Janardhanam, Vanisree Arambakkam ^a   Bradner, James E ^b  

^a UNIVERSITY OF MADRAS   (India)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Akt; Autophagy; Bcl 2; c Myc; Glioblastoma multiforme; Glycogen; Lipid

Indexed keywords

(+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; GLYCOGEN; MYC PROTEIN; TRIAZOLE DERIVATIVE;

ANIMAL; BRAIN TUMOR; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MALE; METABOLISM; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; AZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; GLYCOGEN; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MALE; PROTO-ONCOGENE PROTEINS C-MYC; RATS, WISTAR; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 84930278597     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-014-0083-4     Document Type: Article

References (40)

1. Alcantara Llaguno SR, Chen J, Parada LF (2009) Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. Clin Cancer Res 15:7124–7129. doi:10.1158/1078-0432.ccr-09-0433
2. Bandopadhayay P et al (2013) BET-bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer. doi:10.1158/1078-0432.ccr-13-2281
3. Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV (2013) The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis. J Leukoc Biol. doi:10.1189/jlb.1112588
4. Cheng Z et al (2013) Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 19:1748–1759. doi:10.1158/1078-0432.ccr-12-3066
5. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM (1999) Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 59:1685s–1692s
6. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22:8590–8607. doi:10.1038/sj.onc.1207102
7. Dang CV (1999) c-Myc target genes involved in cell growth. Apoptosis Metab Mol Cell Biol 19:1–11
8. Dang CV (2012) Links between metabolism and cancer. Genes Dev 26:877–890. doi:10.1101/gad.189365.112
9. Darnell JE Jr (2002) Transcription factors as targets for cancer therapy nature reviews. Cancer 2:740–749. doi:10.1038/nrc906
10. De Salvo M et al (2011) Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat Biol 87:518–533. doi:10.3109/09553002.2011.556173
11. Delmore JE et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904–917. doi:10.1016/j.cell.2011.08.017
12. Devan S, Janardhanam VA (2011) Effect of naringenin on metabolic markers, lipid profile and expression of GFAP in C6 glioma cells implanted rat’s brain. Ann Neurosci 18:151–155
13. Evan G, Littlewood T (1998) A matter of life and cell death. Science 281:1317–1322
14. Fan Y, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285:7324–7333. doi:10.1074/jbc.M109.035584
15. Fanidi A, Harrington EA, Evan GI (1992) Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554–556. doi:10.1038/359554a0
16. Favaro E et al (2012) Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 16:751–764. doi:10.1016/j.cmet.2012.10.017
17. Filippakopoulos P et al (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073. doi:10.1038/nature09504
18. Graves JA et al (2012) Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS One 7:e37699. doi:10.1371/journal.pone.0037699
19. Grommes C et al (2006) Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment. Mol Pharmacol 70:1524–1533. doi:10.1124/mol.106.022194
20. Hu S et al. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Blood 121:4021-4031; quiz 4250 doi:10.1182/blood-2012-10-460063
21. Jahani-Asl A, Bonni A (2013) iNOS: a potential therapeutic target for malignant glioma. Curr Mol Med 13:1241–1249
22. Kihara-Negishi F et al (1998) Down-regulation of c-myc and bcl-2 gene expression in PU.1-induced apoptosis in murine erythroleukemia cells international journal of cancer. J Int cancer 76:523–530
23. Kim J, Lee JH, Iyer VR (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PloS one 3:e1798. doi:10.1371/journal.pone.0001798
24. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28:2485–2491. doi:10.1038/onc.2009.112
25. Morrish F et al (2010) Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem 285:36267–36274. doi:10.1074/jbc.M110.141606
26. Murat A et al (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015–3024. doi:10.1200/jco.2007.15.7164
27. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100:2235–2241. doi:10.1111/j.1349-7006.2009.01308.x
28. Pescador N et al (2010) Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PLoS ONE 5:e9644. doi:10.1371/journal.pone.0009644
29. Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21. doi:10.1002/ana.22425
30. Rabinowitz JD, White E (2010) Autophagy and metabolism. Science 330:1344–1348. doi:10.1126/science.1193497
31. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR (2000) Multiple ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501–2514. doi:10.1101/gad.836800
32. Singh R, Cuervo AM (2011) Autophagy in the cellular energetic balance. Cell Metab 13:495–504. doi:10.1016/j.cmet.2011.04.004
33. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128
34. Tang X et al (2013) BET bromodomain proteins mediate downstream signaling events following growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary fibrosis. Mol Pharmacol 83:283–293. doi:10.1124/mol.112.081661
35. Venneti S, Thompson CB (2013) Metabolic modulation of epigenetics in gliomas. Brain Pathol 23:217–221. doi:10.1111/bpa.12022
36. Wu X, Qi J, Bradner JE, Xiao G, Chen LF (2013) Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) tax protein-mediated tumorigenesis by inhibiting nuclear factor kappab (NF-kappaB) signaling. J Biol Chem 288:36094–36105. doi:10.1074/jbc.M113.485029
37. Zeller KI et al (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci 103:17834–17839. doi:10.1073/pnas.0604129103
38. Zhang F, Du G (2012) Dysregulated lipid metabolism in cancer. World j Biol Chem 3:167–174. doi:10.4331/wjbc.v3.i8.167
39. Zhao S et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261–265. doi:10.1126/science.1170944
40. Zirath H et al (2013) MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A 110:10258–10263. doi:10.1073/pnas.1222404110